1270results about "Polypeptide with His-tag" patented technology

A recombinant humanized collagen and a preparation method therefor. The recombinant humanized type III collagen can be efficiently and stably expressed in three expression systems of yeast, Escherichia coli, and CHO cells, and has the biological activity superior to that of a commercially available collagen product. The recombinant humanized type III collagen has structural characteristics and functional activity similar to those of a natural collagen, and thus has wide application prospects in biomedical materials, tissue engineering products, cosmetics, foods, health care products or drugs, medical instruments, medical cosmetology and the like.

The invention discloses a multi-effect repair type collagen and application thereof, and belongs to the technical field of synthetic biology. Transdermal peptide TD-1, a transmembrane region of human XVII type collagen, an extracellular sixteenth non-collagen region, an extracellular fifteenth collagen region and a coding gene of a His tag are selected to be connected in series, and a gene sequence is optimized through pichia pastoris codon selection preference; and then the T-COL17R3 is constructed and expressed to obtain the T-COL17R3. Efficacy experiments prove that compared with similar products sold in the market, T-COL17R3 not only has excellent transdermal performance, but also has better cell proliferation and migration promoting capability, better capability of resisting early saccharification product ketoamine and later saccharification product dicarbonyl compounds, better capability of scavenging free radicals and resisting elastase, and can be used for preparing the anti-epidermal drug. In addition, synthesis of melanin in B16-F10 cells can be reduced, so that T-COL17R3 has excellent application potential in development of pharmaceutical compositions or skin care products with repairing, anti-wrinkle and firming or whitening and brightening effects.

Provided herein are albumin binding proteins and methods of making and using thereof.

The invention specifically discloses a composition for detecting NAD < + > and application thereof, and relates to the technical field of biological detection. According to the composition for detecting NAD < + >, the composition comprises an NAD < + > binding protein fragment A connected with an Fc tag, an NAD < + > binding protein fragment B and a connecting peptide, the detection result is accurate and reliable, and meanwhile the technical difficulty, uncertainty and high cost faced by antibody screening in a traditional method are avoided.

Provided herein are albumin binding proteins and methods of making and using thereof.

The present invention relates to a fusion protein that produces point mutations in cells, its preparation and use. Specifically, the fusion protein provided by the present invention contains a Cas enzyme that lacks cytosine deaminase and nuclease activity and retains helicase activity, or is formed by a Cas enzyme that lacks cytosine deaminase and nuclease activity and retains helicase activity. The present invention also relates to the coding sequence of the fusion protein, a polynucleotide sequence containing the coding sequence, a nucleic acid construct containing the polynucleotide sequence, a corresponding host cell, a method for producing point mutations in a cell, and a kit, etc. By using the present invention, it is possible to achieve site-directed mutagenesis while obtaining high mutation efficiency and a variety of mutation combinations in a specific gene region.

The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.

Provided is a low molecular weight collagen with a 164.88° triple helix structure. Relates to a small molecule collagen, a preparation method and use thereof. The collagen of the present application comprises an amino acid sequence as shown in SEQ ID NO:1 or a variant amino acid sequence after mutation of the amino acid sequence, and the variant amino acid sequence retains the function of the amino acid sequence as shown in SEQ ID NO:1. The amino acid sequence of the collagen of the present application is shorter and has better transdermal absorption performance.

Provided is a method for biosynthesis of a human body structural material type-VIII collagen. Also provided is a collagen, comprising one or more repeating units, wherein the repeating units are connected directly or by means of linkers, and each repeating unit comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, 4, 7, 10, 13, 16, 19, 22, 25 or 28, or a variant thereof. The collagen can be used for biological dressings, human body bionic materials or plastic surgery materials. According to the method, the type-VIII collagen is produced by utilizing a genetic engineering technology, thereby overcoming the defects in the prior art.

The present invention relates to modified Dda helicases which can be used to control the movement of analytes such as polynucleotides. The modified Dda helicases are used in analyte detection and characterisation. The present invention also relates to novel protein pores and their uses in analyte detection and characterisation. The invention particularly relates to an isolated pore complex formed by a CsgG-like pore and a modified CsgF peptide, or a homologue or mutant thereof, thereby incorporating an additional channel constriction or reader head in the nanopore.

Disclosed herein are monospecific and multi-specific antibodies with specificities for one or more of OX40, CD40, 4-1BB, HSA, IL-22, or EGFR. Specifically, the disclosure provides variable heavy (VHH) domains of the antibodies with specificities for one or more of OX40, CD40, 4-1BB, HSA, IL-22, or EGFR, and associated sequences. Further discloses are methods of using the monospecific or multi-specific antibodies for treating ah autoimmune disease.

Relating to the field of biotechnology, disclosed are a recombinant human elastin peptide with anti-aging effects and a use thereof. The recombinant human elastin peptide comprises an amino acid sequence shown in SEQ ID NO:1 or a fragment of the amino acid sequence shown in SEQ ID NO:1, the fragment comprises 30% or more of SEQ ID NO:1, or a mutant of the amino acid sequence shown in SEQ ID NO:1 or the fragment of the amino acid sequence shown in SEQ ID NO:1. A disclosed method for producing elastin peptides by using a yeast expression system enables the targeted synthesis of highly effective protein fragments with 100% homology to human proteins, while achieving low costs and facilitating large-scale production, avoiding animal-derived sources and viral risks. This makes the recombinant human elastin peptide safe for use as an anti-aging and anti-photoaging active ingredient in cosmetics, while also supporting a use thereof in the field of biomedical materials.

The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.

Provided are a recombinant human interleukin-11 mutant, and a conjugate of the mutant conjugated to a chemical molecule and a use thereof. The recombinant human interleukin-11 mutant achieves soluble expression in an Escherichia coli expression system by means of an SUMO sequence tandem fusion method. The conjugate is obtained by the site-specific conjugation of the mutant to the chemical molecule at a mutant amino acid residue in position W147 by means of a covalent bond. The chemical molecule is at least one of polyethylene glycol, an alkanoic acid aliphatic chain, and a hydrophilic high-molecular polymer containing an alkanoic acid aliphatic chain. The conjugate retains the binding capacity to human interleukin-11 receptor A while demonstrating significantly reduced binding capacity to human IL-6 signal transducer receptor. The conjugate shows the ability to block the signaling between human IL-11 and IL-11 RA and between human IL-11 and GP130 either in vivo or in vitro and can be used for the treatment of associated diseases with tissue fibrosis as a clinical manifestation caused by elevated primary or secondary IL-11.

The present application discloses a recombinant humanized type III collagen microsphere with innovative spatial structure, and its design, preparation process, and use. The gene sequence of humanized type III collagen is designed and constructed, and cut by a cutting enzyme and then cyclized by cyclase, obtaining the recombinant humanized type III collagen microspheres with an innovative spatial structure, without introducing any foreign insertion gene or modification gene. The collagen microsphere of the present application exhibits a long degradation time and good stability and durability and can exert its various biological effects for a long time, which can better adapt to applications in the pharmaceutical and cosmetics industries.

The invention belongs to the technical field of food and feed analysis and detection, and particularly provides a nano antibody for detecting bacitracin methylene salicylate, and the nano antibody comprises a nano antibody BMD-BA19 and a nano antibody BMD-CA45; the amino acid sequence of a VHH chain of the nano antibody BMD-BA19 is as shown in SEQ ID NO: 1, and the amino acid sequence of a VHH chain of the nano antibody BMD-CA45 is as shown in SEQ ID NO: 2. The bacitracin methylene salicylate serves as a research object, after the bacitracin methylene salicylate is coupled with protein, an alpaca is immunized, two nano antibodies resisting bacitracin methylene salicylate are obtained through screening with a phage display technology, and a material is provided for establishing a bacitracin methylene salicylate detection method.

The invention relates to the technical field of genetic engineering, in particular to recombinant humanized collagen and a preparation method thereof. The recombinant humanized III-type collagen provided by the invention can be efficiently and stably expressed under three expression systems of yeast, escherichia coli and CHO cells, and has biological activity superior to that of commercially available collagen products. The recombinant humanized III-type collagen disclosed by the invention has structural characteristics and functional activity similar to those of natural collagen, so that the recombinant humanized III-type collagen has wide application prospects in the aspects of biomedical materials, tissue engineering products, cosmetics, foods, health care products or medicines, medical instruments, medical cosmetology and the like.

The invention provides a preparation method, application and the like of large intestine expression recombinant A-type botulinum toxin (BONT / A). The recombinant BONT / A nucleic acid expression cassette comprises a tag, a restriction enzyme cutting site and a BONT / A nucleic acid sequence, and an exogenous protease recognition site is not introduced between a BONT / A light chain and a BONT / A heavy chain. The invention also provides a recombinant vector containing the nucleic acid expression cassette, a recombinant bacterium, a coded and expressed protein and the like, the prepared recombinant BONT / A does not introduce exogenous amino acid or only introduces two amino acids at one position, and the consistency of the recombinant BONT / A with the natural A-type botulinum toxin is ensured to the greatest extent. Through novel molecular design and preparation process, the recombinant reBONT / A with higher toxicity and low immunogenicity is efficiently obtained, and wide industrial application is facilitated.

The present invention discloses a haloalkane dehalogenase and its application in the degradation of 1,2,3-trichloropropane. The haloalkane dehalogenase provided by the present invention is a protein with the amino acid sequence of SEQ ID NO.1. The haloalkane dehalogenase of the present invention has high degradation activity towards the refractory and highly toxic 1,2,3-trichloropropane, and can degrade 42.63% of 1,2,3-trichloropropane after 2 h of reaction, with a fast biodegradation rate; IPTG is used to induce the expression of the haloalkane dehalogenase in recombinant bacteria, and high enzyme activity can be obtained after 5 h of expression. The recombinant bacteria express the haloalkane dehalogenase faster and with higher yields. The haloalkane dehalogenase of the present invention has high activity in a relatively wide pH range (3.0 - 9.0) and temperature range (25°C - 60°C), and has a relatively broad application scope.

Provided are a method for diagnosing cancer, a diagnosis kit and compositions useful for measurement of NK cell activity. The incidence of cancer may be diagnosed by monitoring changes in the in vivo immune system through measurement of NK cell activity in blood. Thus, the incidence of cancer may be readily predicted as described herein using a blood sample from a subject.

The invention discloses a method for improving the solubility and thermal stability of sweet protein, and belongs to the technical field of biosynthesis, the method comprises the following steps: constructing a gene tandem recombinant plasmid containing a monellin x-3C-sfGFP-3C-monellin y expression cassette, x is greater than or equal to 1, y is greater than or equal to 1, 5 is greater than or equal to x + y is greater than or equal to 3, a 3C protease recognition sequence is also inserted between adjacent copies of monellin, and each monellin is connected with a purification tag; the gene tandem recombinant plasmid is transformed into escherichia coli and inducible expression is carried out, thalli are split and purified to obtain fusion protein, 3C protease is used for enzyme digestion, and the target protein is obtained after re-purification. The total protein yield and the solubility proportion are remarkably improved by adopting a series construction mode of plasmids, meanwhile, the stability of monellin is effectively improved, the purification step is simpler and more convenient, and the method is suitable for industrial production.

The invention discloses a recombinant I-type collagen, a preparation method and application, and belongs to the technical field of binding tissue peptides, the recombinant I-type collagen is formed by sequentially connecting the following modules in series from the N terminal to the C terminal: a signal peptide, a truncated I-type collagen and a His tag; the nucleotide sequence of the truncated I type collagen is as shown in any one of SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6; the nucleotide sequence of the truncated I type collagen is as shown in any one of SEQ ID NO.3, SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6; according to the invention, a mammalian expression system and a 293T cell line are used for expressing recombinant I-type collagen, so that collagen with natural biological activity is obtained, and the proliferation efficiency and repair capacity of the collagen for promoting HSF cells can be improved.

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains and its use in a method of treating cancer in a subject.

The present invention relates to nucleic acids coding for a protein said protein comprising a truncated glial fibrillary acidic protein (GFAP), proteins comprising a truncated GFAP, expression constructs comprising a nucleic acid coding for a protein which comprises a truncated GFAP, vectors comprising the nucleic acids or expression constructs disclosed herein and eukaryotic cells comprising a nucleic acid, proteins, expression construct or vector disclosed herein. The present invention furthermore relates to compositions comprising the herein disclosed proteins and kits comprising the herein disclosed proteins and / or compositions. Furthermore, the present invention relates to the use of the herein disclosed proteins, compositions and / or kits for calibrating a measurement system for the in vitro quantification of GFAP or a variant thereof in a sample.

The invention belongs to the technical field of gene engineering, and discloses a cat serum albumin mutant as well as a CHO cell expression method and application thereof. The invention provides a cat serum albumin mutant Mut-FSA for the first time, and an optimized Mut-FSA sequence is finally formed by replacing the 558th K at the tail end of an FSA amino acid sequence with R. Compared with non-mutated FSA, the Mut-FSA can show more remarkable curative effect advantages in treatment intervention of cat hypoproteinemia or acute hemorrhage, in addition, the Mut-FSA not only can enable cats suffering from the hypoproteinemia to achieve rapid correction of serum albumin concentration within 24 hours after treatment intervention, but also can effectively improve the serum albumin level and overall prognosis of the cats. The recombinant FSA prepared by the invention not only can provide a more effective innovative therapy for cat hypoproteinemia or acute hemorrhage, but also has wide application prospect and industrialization value.

Provided herein are methods for preparing and characterizing SARS-co2 antigen specific immune cell cultures and preparations and methods of using the same in adoptive immunotherapy for cancer, infections and immune disorders. Also, provided are compositions and methods for generating immune cells expressing synthetic antigen binding receptors targeting SARS-cov2 and methods of use of these cells for the treatment and prevention of COVID-19. Also provided are compositions and methods for determining immune response to SARs-cov2 in a subject, detecting SARS-cov2, measuring cytotoxicity induced by SARS-cov2, and detecting the expression and cytotoxicity of synthetic antigen binding receptors targeting SARS-cov2.

The present invention provides, in various embodiments, electrically conductive protein nanowires (e-PNs) having surface exposed peptides that confer additional sensing capabilities and / or enhance binding to other materials, as well as fusion proteins and methods for making such nanowires. The present invention also provides sensor devices comprising the nanowires.

Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, and 6-12, or amino acid sequences that are about 95% identical thereto, and fragments thereof. Also provided are scFv peptides that include a VH segment having a first amino acid sequence of amino acids 4-113 of any one of SEQ ID NOs: 2 and 8-12, a VL segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and / or target conformational states of FN in samples; methods for treating diseases and / or disorders and / or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.

The invention belongs to the technical field of biology, and particularly relates to a receptor peptidomimetic capable of improving the breeding efficiency of butter crabs and application of the receptor peptidomimetic. The optimal binding conformation is screened according to the sequence prediction binding conformation of the vitellogen and the receptor of the vitellogen, the hotspot residues are screened according to the optimal binding conformation, and the binding energy change before and after mutation of the hotspot residues is calculated to determine the receptor peptidomimetic sequence. The receptor peptidomimetic can obviously slow down the development speed of the ovary of the blue crab and effectively induce the formation of the butter crab by utilizing the specificity of specific recognition of the vitellogenin of the blue crab and the receptor, so that the butter crab product can be produced in a planned manner.

The present disclosure relates to a polypeptide construct for targeted delivery of a payload, comprising a natriuretic peptide receptor (NPR-C) ligand. Also provided is a conjugate comprising; a polypeptide construct for targeted delivery of a payload to NPR-C expressing cells. Further provided are compositions comprising the construct or the conjugate, and kits comprising the construct and a crosslinker, and methods and uses of the same.